• Pioneering a novel approach to dose escalation in radiotherapy–DDR inhibitor trials that reduce delays by testing multiple agents in parallel

• Applying adaptive statistical methods enabling faster determination of safe, effective doses

• Extending early data from lung cancer studies to brain tumors and other hard-to-treat cancers